AI Article Synopsis
- Advanced cutaneous T cell lymphoma (CTCL) has a poor prognosis, especially for patients who relapse after systemic treatments, with no curative options currently available.
- New therapies are improving disease-free survival and have manageable side effects, while allogeneic stem cell transplantation (allo-SCT) offers the longest disease-free survival for suitable patients.
- The article reviews current research on allo-SCT for CTCL, including the timing of the procedure and new therapies that may enhance outcomes before the transplant.
Article Abstract
Advanced cutaneous T cell lymphoma (CTCL) patients have a dismal prognosis, especially those relapsing or progressing after systemic therapy. No curative therapies are available, but some new agents have prolonged disease-free survival time with a good toxicity profile. Allogeneic stem cell transplantation (allo-SCT) offers the longest disease-free survival, potentially representing the best therapeutic option for eligible patients. In the present article, we discuss current evidence about allo-SCT for CTCL patients, timing, and new therapeutic options before allo-SCT, taking into account some considerations that may impact clinical outcome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12185-019-02707-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!